Stem Cell Transplants in Childhood Neuroblastoma Improves Immunotherapy Outcomes

Published 2023-08-10

A recently published study in the Journal of Clinical Oncology points to improved outcomes from Cancer Immunotherapy (dinutuximab beta) following Stem Cell Transplantation from parent donors. 5 year survival exceeded 50% compared to 23% with traditional treatments. The additional benefit from the Stem Cell Transplantation likely resides in the formation of new Natural Killer cells in the recipient which appears to augment the Immunotherapy agent.